UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000017775
Receipt No. R000020568
Scientific Title Evaluation of the safety on hemodiafilter "AMPA-01" in renal failure patients.
Date of disclosure of the study information 2015/06/03
Last modified on 2015/10/28

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Evaluation of the safety on hemodiafilter "AMPA-01" in renal failure patients.
Acronym Evaluation of the safety on AMPA-01.
Scientific Title Evaluation of the safety on hemodiafilter "AMPA-01" in renal failure patients.
Scientific Title:Acronym Evaluation of the safety on AMPA-01.
Region
Japan

Condition
Condition Maintenance dialysis patients who are indicated for hemodiafiltration.
Classification by specialty
Nephrology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To evaluate the safety of hemodiafiltration using "AMPA-01" in maintenance dialysis patients who are indicated for hemodiafiltration.
Basic objectives2 Safety
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase Phase III

Assessment
Primary outcomes 1) The frequency of acute failure such as adverse events which is suspected to be caused by "AMPA-01".
2) Blood compatibility (Fluctuations in the number of white blood cells and platelets during hemodiafiltration.)
Key secondary outcomes 1) clearance
2) reduction rate
3) removal amount
4) protein leakage
5) transmembrane pressure

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Device,equipment
Interventions/Control_1 Hemodiafiltration using AMPA-01
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
80 years-old >
Gender Male and Female
Key inclusion criteria 1) Maintenance dialysis patients corresponding to
- three times per week
- more than three and a half hours in each dialysis session
- hemodialysis or hemodiafiltration for more than six months
- last one month received hemodiafiltration.
2) Qb 250 mL/min is possible when the effectiveness evaluation.
3) Outpatients.
4) Ability to give written informed consent.
5) Aged 20 to <80 years at the time of informed consent.
Key exclusion criteria 1) Need to blood purification other than AMPA-01.
2) With a medical history of anaphylaxis symptoms caused by polysulfone or polyvinylpyrrolidone (PVP).
3) Pregnant women or lactating mothers
4) With severe organ dysfunction other than kidney.
5) Patients who had participated in other clinical trial within the previous 6 months.
6) Judged ineligible by the attending physician.
Target sample size 12

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name HASHIMOTO Shinji
Organization ASAHI KASEI MEDICAL CO., LTD.
Division name Clinical Development Department
Zip code
Address 1-105 Kanda Jinbocho, Chiyoda-ku, Tokyo
TEL 03-3296-3787
Email hashimoto.sg@om.asahi-kasei.co.jp

Public contact
Name of contact person
1st name
Middle name
Last name OHSHIMA Koji
Organization ASAHI KASEI MEDICAL CO., LTD.
Division name Clinical Development Department
Zip code
Address 1-105 Kanda Jinbocho, Chiyoda-ku, Tokyo
TEL 03-3296-3787
Homepage URL
Email oshima.kb@om.asahi-kasei.co.jp

Sponsor
Institute ASAHI KASEI MEDICAL CO., LTD.
Institute
Department

Funding Source
Organization ASAHI KASEI MEDICAL CO., LTD.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW 平成27年4月13日

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2015 Year 06 Month 03 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2015 Year 04 Month 23 Day
Date of IRB
Anticipated trial start date
2015 Year 06 Month 08 Day
Last follow-up date
2015 Year 08 Month 31 Day
Date of closure to data entry
Date trial data considered complete
2015 Year 10 Month 20 Day
Date analysis concluded

Other
Other related information

Management information
Registered date
2015 Year 06 Month 02 Day
Last modified on
2015 Year 10 Month 28 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020568

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.